NCT03201692

Brief Summary

Balance and gait problems in subjects with neurological disease lead to reduced mobility, loss of independence and frequent falls. Treadmill training is a widely used form of treatment and it has been used in subjects with neurological disease to ameliorate walking and balance deficits. The Virtual Reality Treadmill as a therapeutic tool has been recently introduced to practice gait adaptability elicited by aligning foot placement relative to the projected visual context. Forty-eight subjects with neurological disease will receive treadmill training treatment randomly divided in Traditional Treadmill training and Virtual Reality Treadmill training. The aim of this randomized controlled study is to assess whether Treadmill training with Virtual Reality is better than Traditional Treadmill training in improving dynamic balance and cognitive aspects in subjects with neurological diseases.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
48

participants targeted

Target at P50-P75 for not_applicable multiple-sclerosis

Timeline
Completed

Started Jul 2017

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 9, 2017

Completed
19 days until next milestone

First Posted

Study publicly available on registry

June 28, 2017

Completed
3 days until next milestone

Study Start

First participant enrolled

July 1, 2017

Completed
1.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 10, 2019

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 10, 2019

Completed
Last Updated

July 27, 2017

Status Verified

July 1, 2017

Enrollment Period

1.8 years

First QC Date

June 9, 2017

Last Update Submit

July 25, 2017

Conditions

Outcome Measures

Primary Outcomes (2)

  • Change in the Modified Dynamic Gait Index

    Tool used to assess dynamic balance

    Change from Baseline Modified Dynamic Gait Index scores at 3-5 weeks

  • Change in the 6 minutes walking test

    tool used to assess walking endurance

    Change from Baseline 6 minutes walking test scores at 3-5 weeks

Secondary Outcomes (4)

  • Change in Activity Balance Confidence

    Change from Baseline Activity Balance Confidence scores at 3-5 weeks

  • Change in 10-meter walking test

    Change from Baseline10-meter walking test scores at 3-5 weeks

  • Change in Trial Making test

    Change from Baseline Trial Making test scores at 3-5 weeks

  • Change in Raven's Matrices

    Change from Baseline Raven's Matrices scores at 3-5 weeks

Study Arms (2)

Treadmill Training

ACTIVE COMPARATOR

40' treadmill training walking holding the handrail

Device: Treadmill training

Virtual Reality Treadmill Training

EXPERIMENTAL

40' treadmill training walking with virtual visual and auditory cues

Device: Virtual Reality Treadmill Training

Interventions

Subjects in the experimental group will receive 40 minutes comprising exercises focused on improving dynamic balance following auditory and visual cues.

Also known as: C-mill treadmill
Virtual Reality Treadmill Training

Subjects in the active comparator group will receive 40 minutes walking training aimed to improve velocity and endurance.

Treadmill Training

Eligibility Criteria

Age20 Years - 85 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Diagnosis of Multiple Sclerosis (no relapse within the previous three months;), Parkinsons Disease (Hoenhn and Yahr Scale ≤4), Stroke (Time from onset \>2 months)
  • Able to walk 20 meters with or without assistive device
  • Cognitive impairment (MMSE score ≥ 21)

You may not qualify if:

  • Unable to understand the aim of the study and unable to sign the informed consent
  • Steroidal drugs therapy for subjects with Multiple Sclerosis
  • Subjects with Psychiatric disorders
  • Subjects with Visual impairments
  • Subjects with cardiovascular disease

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Don Gnocchi Foundation

Milan, 20148, Italy

RECRUITING

MeSH Terms

Conditions

Multiple SclerosisStrokeParkinson Disease

Condition Hierarchy (Ancestors)

Demyelinating Autoimmune Diseases, CNSAutoimmune Diseases of the Nervous SystemNervous System DiseasesDemyelinating DiseasesAutoimmune DiseasesImmune System DiseasesCerebrovascular DisordersBrain DiseasesCentral Nervous System DiseasesVascular DiseasesCardiovascular DiseasesParkinsonian DisordersBasal Ganglia DiseasesMovement DisordersSynucleinopathiesNeurodegenerative Diseases

Central Study Contacts

Paolo MOcarelli, MD

CONTACT

Davide Cattaneo, PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Research Coordinator, LaRiCE Lab, PhD

Study Record Dates

First Submitted

June 9, 2017

First Posted

June 28, 2017

Study Start

July 1, 2017

Primary Completion

April 10, 2019

Study Completion

April 10, 2019

Last Updated

July 27, 2017

Record last verified: 2017-07

Data Sharing

IPD Sharing
Will not share

Locations